Citations

Showing 10 of 108162 citations.

Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials
Kashour, Zakariya , Kashour, Tarek , Gerberi, Dana , Tleyjeh, Imad M. , Gerberi, Danielle, Tleyjeh, Imad M

Mayo Clinic

Clinical and Translational Science | February 19, 2021 | Volume: 14 | Issue: 3 | Pages: 1101-1112

10.1111/cts.13001 | PMID 33606894 Get It

AbstractMany meta‐analyses have been published about the efficacy of hydroxychloroquine (HCQ) in coronavirus disease 2019 (COVID‐19). Most of them included observational studies, and few have assessed HCQ as a prophylaxis or evaluated its safety profile. We searched multiple databases and preprint servers for randomized controlled trials (RCTs) that assessed HCQ for the treatment or prevention of COVID‐19. We summarized the effect of HCQ on mortality, viral clearance, and other clinical outcomes. Out of 768 papers screened, 21 RCTs with a total of 14,138 patients were included. A total of 9 inpatient and 3 outpatient RCTs assessed mortality in 8596 patients with a pooled risk difference of 0.01 (95% confidence interval [CI] 0.00–0.03, I2 = 1%, p = 0.07). Six studies assessed viral clearance at 7 days with a pooled risk ratio (RR) of 1.11 (95% CI 0.86–1.42, I2 = 61%, p = 0.44) and 5 studies at 14 days with a pooled RR of 0.96 (95% CI 0.89–1.04, I2 = 0%, p = 0.34). Several trials showed no significant effect of HCQ on other clinical outcomes and. Five prevention RCTs with 5012 patients found no effect of HCQ on the risk of acquiring COVID‐19. Thirteen trials showed that HCQ was associated with increased risk of adverse events. We observed, with high level of certainty of evidence, that HCQ is not effective in reducing mortality in patients with COVID‐19. Lower certainty evidence also suggests that HCQ neither improves viral clearance and other clinical outcomes, nor prevents COVID‐19 infection in patients with high‐risk exposure. HCQ is associated with an increased rate of adverse events.
Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries
Hurson, Amber N. , Choudhury, Parichoy Pal , Gao, Chi , Eriksson, Mikael , Shi, Min , Jones, Michael E. , Evans, D. Gareth , Gaudet, Mia M. , Vachon, Celine M. , Easton, Douglas F. , García‐Closas, Montserrat , Chatterjee, Nilanjan , Group, for the B-CAST Risk Modelling, Simard, Jacques , Newman, William G. , Veen, Elke M. van , Harkness, Elaine F. , Chasman, Daniel I , Evans, D Gareth , Jones, Michael E , Newman, William G , García-Closas, Montserrat , Simard, Jacques , Eriksson, Mikael , Hüsing, Anika , Milne, Roger L. , Vachon, Celine M. , Chasman, Daniel I. , Schmidt, Marjanka K. , Kraft, Peter , Group, for the B-CAST Risk Modelling

Mayo Clinic

International Journal of Epidemiology | February 19, 2021 | Volume: 50 | Issue: 6 | Pages: 1897-1911

10.1093/ije/dyab036 | PMID 34999890 Get It

Abstract Background Rigorous evaluation of the calibration and discrimination of breast-cancer risk-prediction models in prospective cohorts is critical for applications under clinical guidelines. We comprehensively evaluated an integrated model incorporating classical risk factors and a 313-variant polygenic risk score (PRS) to predict breast-cancer risk. Methods Fifteen prospective cohorts from six countries with 239 340 women (7646 incident breast-cancer cases) of European ancestry aged 19–75 years were included. Calibration of 5-year risk was assessed by comparing expected and observed proportions of cases overall and within risk categories. Risk stratification for women of European ancestry aged 50–70 years in those countries was evaluated by the proportion of women and future cases crossing clinically relevant risk thresholds. Results Among women <50 years old, the median (range) expected-to-observed ratio for the integrated model across 15 cohorts was 0.9 (0.7–1.0) overall and 0.9 (0.7–1.4) at the highest-risk decile; among women ≥50 years old, these were 1.0 (0.7–1.3) and 1.2 (0.7–1.6), respectively. The proportion of women identified above a 3% 5-year risk threshold (used for recommending risk-reducing medications in the USA) ranged from 7.0% in Germany (∼841 000 of 12 million) to 17.7% in the USA (∼5.3 of 30 million). At this threshold, 14.7% of US women were reclassified by adding the PRS to classical risk factors, with identification of 12.2% of additional future cases. Conclusion Integrating a 313-variant PRS with classical risk factors can improve the identification of European-ancestry women at elevated risk who could benefit from targeted risk-reducing strategies under current clinical guidelines.
Harnessing brain waves: a review of brain magnetic resonance elastography for clinicians and scientists entering the field
Arani, Arvin , Huston Iii, John, Arani, Arvin , Manduca, Armando , Ehman, Richard L. , Huston, John

Mayo Clinic

The British Journal of Radiology | February 19, 2021 | Volume: 94 | Issue: 1119 | Pages: No page available

10.1259/bjr.20200265 | PMID 33605783 Get It

Brain magnetic resonance elastography (MRE) is an imaging technique capable of accurately and non-invasively measuring the mechanical properties of the living human brain. Recent studies have shown that MRE has potential to provide clinically useful information in patients with intracranial tumors, demyelinating disease, neurodegenerative disease, elevated intracranial pressure, and altered functional states. The objectives of this review are: (1) to give a general overview of the types of measurements that have been obtained with brain MRE in patient populations, (2) to survey the tools currently being used to make these measurements possible, and (3) to highlight brain MRE-based quantitative biomarkers that have the highest potential of being adopted into clinical use within the next 5 to 10 years. The specifics of MRE methodology strategies are described, from wave generation to material parameter estimations. The potential clinical role of MRE for characterizing and planning surgical resection of intracranial tumors and assessing diffuse changes in brain stiffness resulting from diffuse neurological diseases and altered intracranial pressure are described. In addition, the emerging technique of functional MRE, the role of artificial intelligence in MRE, and promising applications of MRE in general neuroscience research are presented.
Clinician Satisfaction with Rapid Adoption and Implementation of Telehealth Services During the COVID-19 Pandemic
Gentry, Melanie T. , Puspitasari, Ajeng J. , McKean, Alastair J. , Williams, Mark D. , Breitinger, Scott , Geske, Jennifer R. , Clark, Matthew M. , Moore, Katherine M. , Frye, Mark A. , Gentry, Melanie T , Geske, Jennifer , Hilty, Donald M.

Mayo Clinic

Telemedicine and e-Health | February 19, 2021 | Volume: 27 | Issue: 12 | Pages: 1385-1392

10.1089/tmj.2020.0575 | PMID 33606560 Get It

Ethnic variability associating gut and oral microbiome with obesity in children
Balakrishnan, Baskar , Selvaraju, Vaithinathan , Ayine, Priscilla , Yang, Lu , Geetha, Thangiah , Taneja, Veena , Babu, Jeganathan Ramesh , Geetha, Thangiah , Taneja, Veena , Balakrishnan, Baskar , Chen, Jun , Babu, Jeganathan Ramesh

Mayo Clinic

Gut Microbes | February 19, 2021 | Volume: 13 | Issue: 1 | Pages: No page available

10.1080/19490976.2021.1882926 | PMID 33596768 Get It

Common genetic polymorphisms contribute to the association between chronic lymphocytic leukaemia and non-melanoma skin cancer
Besson, Caroline , Moore, Amy , Wu, Wenting , Vajdic, Claire M. , Sanjosé, Sílvia de, Camp, Nicola J. , Smedby, Karin E. , Morton, Lindsay M. , Brewer, Jerry D., Han, Jiali , Berndt, Sonja I. , Link, Brian K. , Wang, Sophia , Staines, Anthony , Melbye, Mads , Diver, W. Ryan , Vermeulen, Roel , Kleinstern, Geffen , Clavel, Jacqueline , Miligi, Lucia , Cerhan, James R , Han, Jiali , Link, Brian K , Vajdic, Claire M , Morton, Lindsay M , Wang, Sophia S , Clavel, Jacqueline , Shanafelt, Tait D. , Zablotska, Lydia B. , Engels, Eric A. , Cerhan, James R. , Slager, Susan L.

Mayo Clinic

International Journal of Epidemiology | February 19, 2021 | Volume: 50 | Issue: 4 | Pages: 1325-1334

10.1093/ije/dyab042 | PMID 33748835 Get It

AbstractBackgroundEpidemiological studies have demonstrated a positive association between chronic lymphocytic leukaemia (CLL) and non-melanoma skin cancer (NMSC). We hypothesized that shared genetic risk factors between CLL and NMSC could contribute to the association observed between these diseases.MethodsWe examined the association between (i) established NMSC susceptibility loci and CLL risk in a meta-analysis including 3100 CLL cases and 7667 controls and (ii) established CLL loci and NMSC risk in a study of 4242 basal cell carcinoma (BCC) cases, 825 squamous cell carcinoma (SCC) cases and 12802 controls. Polygenic risk scores (PRS) for CLL, BCC and SCC were constructed using established loci. Logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs).ResultsHigher CLL-PRS was associated with increased BCC risk (OR4th-quartile-vs-1st-quartile = 1.13, 95% CI: 1.02–1.24, Ptrend = 0.009), even after removing the shared 6p25.3 locus. No association was observed with BCC-PRS and CLL risk (Ptrend = 0.68). These findings support a contributory role for CLL in BCC risk, but not for BCC in CLL risk. Increased CLL risk was observed with higher SCC-PRS (OR4th-quartile-vs-1st-quartile = 1.22, 95% CI: 1.08–1.38, Ptrend = 1.36 × 10–5), which was driven by shared genetic susceptibility at the 6p25.3 locus.ConclusionThese findings highlight the role of pleiotropy regarding the pathogenesis of CLL and NMSC and shows that a single pleiotropic locus, 6p25.3, drives the observed association between genetic susceptibility to SCC and increased CLL risk. The study also provides evidence that genetic susceptibility for CLL increases BCC risk.
Impact of surgeon and hospital factors on surgical decision-making for grade 1 degenerative lumbar spondylolisthesis: a Quality Outcomes Database analysis
Huang, Meng , Buchholz, Avery L., Bisson, Erica F. , Potts, Eric A. , Knightly, John J. , Coric, Domagoj , Asher, Anthony L. , Foley, Kevin T. , Mummaneni, Praveen V. , Park, Paul , Shaffrey, Mark E., Fu, Kai-Ming, Slotkin, Jonathan R., Glassman, Steven D. , Bydon, Mohamad , Wang, Michael , Goyal, Anshit , Ghogawala, Zoher , Fu, Kai-Ming, Wang, Michael

Mayo Clinic

Journal of Neurosurgery: Spine | February 19, 2021 | Volume: 34 | Issue: 5 | Pages: 768-778

10.3171/2020.8.spine201015 | PMID 33607612 Get It

OBJECTIVE Surgical treatment for degenerative spondylolisthesis has been proven to be clinically challenging and cost-effective. However, there is a range of thresholds that surgeons utilize for incorporating fusion in addition to decompressive laminectomy in these cases. This study investigates these surgeon- and site-specific factors by using the Quality Outcomes Database (QOD). METHODS The QOD was queried for all cases that had undergone surgery for grade 1 spondylolisthesis from database inception to February 2019. In addition to patient-specific covariates, surgeon-specific covariates included age, sex, race, years in practice (0–10, 11–20, 21–30, > 30 years), and fellowship training. Site-specific variables included hospital location (rural, suburban, urban), teaching versus nonteaching status, and hospital type (government, nonfederal; private, nonprofit; private, investor owned). Multivariable regression and predictor importance analyses were performed to identify predictors of the treatment performed (decompression alone vs decompression and fusion). The model was clustered by site to account for site-specific heterogeneity in treatment selection. RESULTS A total of 12,322 cases were included with 1988 (16.1%) that had undergone decompression alone. On multivariable regression analysis clustered by site, adjusting for patient-level clinical covariates, no surgeon-specific factors were found to be significantly associated with the odds of selecting decompression alone as the surgery performed. However, sites located in suburban areas (OR 2.32, 95% CI 1.09–4.84, p = 0.03) were more likely to perform decompression alone (reference = urban). Sites located in rural areas had higher odds of performing decompression alone than hospitals located in urban areas, although the results were not statistically significant (OR 1.33, 95% CI 0.59–2.61, p = 0.49). Nonteaching status was independently associated with lower odds of performing decompression alone (OR 0.40, 95% CI 0.19–0.97, p = 0.04). Predictor importance analysis revealed that the most important determinants of treatment selection were dominant symptom (Wald χ2 = 34.7, accounting for 13.6% of total χ2) and concurrent diagnosis of disc herniation (Wald χ2 = 31.7, accounting for 12.4% of total χ2). Hospital teaching status was also found to be relatively important (Wald χ2 = 4.2, accounting for 1.6% of total χ2) but less important than other patient-level predictors. CONCLUSIONS Nonteaching centers were more likely to perform decompressive laminectomy with supplemental fusion for spondylolisthesis. Suburban hospitals were more likely to perform decompression only. Surgeon characteristics were not found to influence treatment selection after adjustment for clinical covariates. Further large database registry experience from surgeons at high-volume academic centers at which surgically and medically complex patients are treated may provide additional insight into factors associated with treatment preference for degenerative spondylolisthesis.
Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial
Jatoi, Aminah , Ahn, Daniel H. , Ciombor, Kristen K. , Jacobs, Nisha L. , Pasche, Boris , Cleary, James M. , McCune, Jeannine S. , Pedersen, Katrina S. , Chiorean, E. Gabriela , Heying, Erica N., Lenz, Heinz‐Josef , Sloan, Jeff A. , Bekaii‐Saab, Tanios , Zemla, Tyler J, Bekaii-Saab, Tanios S , Pedersen, Katrina , Ou, Fang‐Shu , Zemla, Tyler , Le‐Rademacher, Jennifer , Boland, Patrick M. , Barzi, Afsaneh , Grothey, Axel , Lacouture, Mario E.

Mayo Clinic

The Oncologist | February 19, 2021 | Volume: 26 | Issue: 7 | Pages: 610-618

10.1002/onco.13730 | PMID 33604969 Get It

Abstract Background Hand-foot skin reaction (HFSR) is the most common regorafenib-induced adverse event and is in need of effective prevention and palliation. Materials and Methods The Regorafenib Dose Optimization Study (ReDOS), a four-arm, previously published trial with a 1:1:1:1 randomization scheme, was analyzed in a manner in keeping with the original protocol to assess whether clobetasol 0.05% cream (a corticosteroid) applied to the palms and soles twice per day for 8 weeks was more effective when prescribed preemptively (before the development of HFSR) versus reactively (after the development of HFSR). Patients were assessed during the first two cycles of regorafenib. Results Sixty-one patients received preemptive clobetasol, and 55 received reactive clobetasol. Groups were balanced on demographics. Over the first two cycles, no evidence of HFSR occurred in 30% with preemptive clobetasol versus 13% with reactive clobetasol (p = .03). During the first cycle, 54% and 45% of patients had no HFSR with preemptive and reactive clobetasol, respectively (p = .35). During the second cycle, 33% and 15% had no HFSR with preemptive and reactive clobetasol, respectively (p = .02). During the second cycle, rates of grade 1, 2, and 3 HFSR were 30%, 8%, and 3%, respectively, with preemptive clobetasol and 43%, 18%, and 7%, respectively, with reactive clobetasol (p = .12). Patient-reported outcomes showed HFSR compromised nearly all activities of daily living with worse quality of life in patients who received reactive versus preemptive clobetasol. No clobetasol-induced adverse events were reported. Conclusion Preemptive clobetasol might lessen regorafenib-induced hand-foot reactions compared with reactive therapy. Further confirmatory studies are needed in a larger patient cohort. Implications for Practice Regorafenib causes hand-foot skin reactions. Preemptive clobetasol, a high-potency topical corticosteroid, appears to lessen the severity of this adverse event. Although further study is needed, the favorable adverse event profile of this intervention might prompt clinicians to discuss this option with their patients.
Granulomatosis With Polyangiitis and Microscopic Polyangiitis: A Systematic Review and Meta‐Analysis of Benefits and Harms of Common Treatments
Springer, Jason , Kalot, Mohamad A. , Husainat, Nedaa , Byram, Kevin , Dua, Anisha B. , Lin, Yih Chang, Turgunbaev, Marat, Villa‐Forte, Alexandra, Abril, Andy , Langford, Carol A. , Maz, Mehrdad , Springer, Jason M , Husainat, Nedaa M , Byram, Kevin W , Mustafa, Reem A , Kalot, Mohamad A , Dua, Anisha B , James, Karen E., Chung, Sharon A.

Mayo Clinic

ACR Open Rheumatology | February 19, 2021 | Volume: 3 | Issue: 3 | Pages: 196-205

10.1002/acr2.11230 | PMID 33590973 Get It

ObjectiveThe aim of this systemic review is to compare different treatments for patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) to inform evidence‐based recommendations for the American College of Rheumatology (ACR)/Vasculitis Foundation (VF) Vasculitis Management Guidelines.MethodsA systemic review was conducted by searching articles in English using OVID Medline, PubMed, Embase, and the Cochrane Library. Articles were screened for suitability in addressing PICO questions, with studies presenting the highest level of evidence given preference.ResultsA total of 729 full‐text articles addressing GPA and MPA PICO questions were reviewed. For remission induction, rituximab was shown to be noninferior to cyclophosphamide (CYC) (odds ratio [OR]: 1.55, moderate certainty of evidence). The addition of plasma exchange to induction therapy in severe disease did not improve the composite end point of death or end stage renal disease (hazard ratio [HR]: 0.86 [95% confidence interval CI: 0.65, 1.13], moderate certainty of evidence). In nonsevere disease, methotrexate was noninferior to CYC for induction of remission (remission at 6 months of 90% vs. 94%). For maintenance of remission, methotrexate and azathioprine showed no difference in the risk of relapse over a mean follow‐up of 29 months (HR: 0.92, [95% CI: 0.52, 1.65]low certainty of evidence). As maintenance therapy, rituximab was superior to a tapering azathioprine strategy in major relapse‐free survival at 28 months (HR: 6.61, [95% CI: 1.56, 27.96], moderate certainty of evidence). In two randomized trials, longer‐term azathioprine maintenance therapy (>24 months) is associated with fewer relapses without an increase in adverse events.ConclusionThis comprehensive systematic review synthesizes and evaluates the benefits and toxicities of different treatment options for GPA and MPA.
Liquid Biopsy in Cholestatic Liver Disease Using Hepatocyte-Specific Methylation Markers
Punia, Sohan, Juran, Brian D., Ali, Ahmad H. , Schlicht, Erik M., Moore, Raymond M. , Sun, Zhifu , Lazaridis, Konstantinos N.

Mayo Clinic

No container title available | February 19, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-209005/v1 Get It

Abstract Background: Quantification of circulating organ-specific cell-free DNA (cfDNA) provides a sensitive measure of ongoing cell death that could benefit evaluation of the cholestatic liver diseases primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), which lack reliable non-invasive biomarkers. Our goal in this pilot study was to determine whether liver-specific cfDNA levels are increased in PBC and PSC patients relative to controls and in advanced versus early disease, to evaluate their potential as novel disease biomarkers.Methods: Peripheral blood derived bisulfite-treated DNA was PCR amplified from patients with PBC (n=48), PSC (n=48) and controls (n=96) to evaluate methylation status at 16 CpG sites reported to be specifically unmethylated in liver tissue near the genes IGF2R, ITIH4 and VTN. Amplicons were used to prepare paired end libraries which were sequenced on a MiSeq sequencer. Trimmed reads were aligned and used to determine unmethylation ratios and to calculate concentration of liver-specific cfDNA. Comparisons between groups were performed using the two-tailed Mann-Whitney Test and relationships between variables were evaluated using Pearson’s Correlation. Results: Levels of liver-specific cfDNA, as measured at the 3 genetic loci, were increased in PBC and PSC patients relative to controls and in late-stage relative to early-stage patients. As well, cfDNA levels were correlated with levels of alkaline phosphatase, a commonly used biochemical test to evaluate disease severity in liver disease, in patients, but not in controls. Conclusions: cfDNA offers promise as a non-invasive liquid-biopsy to evaluate liver-specific cell-death in patients with cholestatic liver diseases.